Bard’s LifeStent Gets Legs: PMA Approved For Femoral, Popliteal Arteries
This article was originally published in The Gray Sheet
C.R. Bard is now able to market its LifeStent for treating occluded leg arteries with a PMA approval announced Feb. 17
You may also be interested in...
Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.
The presence of the first drug-eluting stent on the U.S. market to treat peripheral artery disease is certainly not the end of the discussion for how peripheral artery patients will be treated, clinicians made clear at the influential Veith Symposium this month.
Clinical data news from the Transcatheter Cardiovascular Therapeutics conference held last week in Miami.